EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Regulatory news and changes

What does the proposed 503B bulks-list exclusion change?

Dose Diligence research deskSection 04 · Page 6 of 17Last updated 18 Nov 2026

Editorial clarification · November 18, 2026. The research below was recorded on November 17, 2026. FDA extended the original June 30 comment deadline to July 30, 2026. Read the June 26 extension notice. The original research text is retained below.

It is an adverse policy development for the nominated bulk-compounding pathway, but it must still be described as a proposal. FDA announced its position on April 30, 2026; the Federal Register notice was published May 1, with comments due June 30. FDA proposed not including semaglutide, tirzepatide and liraglutide after its clinical-need evaluation. No superseding final determination was located in this review. Federal Register notice. (federalregister.gov)

The underlying 503B bulk-substance condition is separate from the copy analysis. A claimed clinical difference does not itself satisfy the requirement governing which bulk substances an outsourcing facility may use. FDA’s published GLP-1 reminder states that semaglutide and tirzepatide are not on its 503B bulks list or shortage list. Section 503B; FDA reminder. (uscode.house.gov)

Buyer action: require counsel to identify the actual starting material and every condition relied upon. Do not accept “503B,” “B12 added,” or “not yet finally excluded” as the complete legal basis.

Sources cited on this page

  1. federalregister.gov · Source 1 ↗https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
  2. federalregister.gov · Source 2 ↗https://www.federalregister.gov/documents/2026/05/01/2026-08552/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
  3. uscode.house.gov · Source 3 ↗https://uscode.house.gov/us/usc/119-136/t21/s353b/
  4. fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
  5. uscode.house.gov · Source 5 ↗https://uscode.house.gov/us/usc/119-136/t21/s353b/?utm_source=openai
Section sources →